UroGen Pharma Ltd. SEC filings URGN
UroGen Pharma Ltd. has 583 filings in SEC EDGAR's recent list, going back to Mar 4, 2016. Its latest annual report, Form ARS, was filed on May 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Nov 4, 2026 | — |
| S-8 | Employee stock plan registration | Nov 6, 2025 | — |
| S-3ASR | Automatic shelf registration | Nov 6, 2025 | — |
| S-8 | Employee stock plan registration | Aug 13, 2024 | — |
| 424B5 | Prospectus supplement | Jun 18, 2024 | — |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| S-8 | Employee stock plan registration | Nov 14, 2023 | — |
| S-3 | Shelf registration | Sep 8, 2023 | — |
| 424B5 | Prospectus supplement | Dec 1, 2022 | — |
| S-3/A | Form s-3/a | Nov 16, 2022 | — |
| S-3 | Shelf registration | Nov 15, 2022 | — |
| S-8 | Employee stock plan registration | Aug 11, 2022 | — |
| S-8 | Employee stock plan registration | Mar 21, 2022 | — |
| S-8 | Employee stock plan registration | Aug 5, 2021 | — |
| S-8 | Employee stock plan registration | Aug 10, 2020 | — |
| 424B5 | Prospectus supplement | Jan 2, 2020 | — |
| S-3 | Shelf registration | Dec 20, 2019 | — |
| S-8 | Employee stock plan registration | Jun 7, 2019 | — |
| 424B5 | Prospectus supplement | Jan 25, 2019 | — |
| 424B5 | Prospectus supplement | Jan 22, 2019 | — |
| S-8 | Employee stock plan registration | Oct 12, 2018 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 12, 2018 | — |
| S-8 | Employee stock plan registration | Feb 9, 2018 | — |
| 424B4 | Prospectus | Jan 22, 2018 | — |
| F-1MEF | Filing | Jan 18, 2018 | — |
| F-1 | Registration statement (foreign issuer) | Jan 16, 2018 | — |
| S-8 | Employee stock plan registration | Oct 30, 2017 | — |
| S-8 | Employee stock plan registration | Jun 27, 2017 | — |
| 424B4 | Prospectus | May 5, 2017 | — |
| F-1MEF | Filing | May 3, 2017 | — |
| F-1/A | Amendment no. 1 to form f-1 | Apr 24, 2017 | — |
| F-1 | Registration statement (foreign issuer) | Apr 7, 2017 | — |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- URGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ra'Anana, Israel
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1668243
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.